IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. The firm is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. The company advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Follow-Up Questions
Who is the CEO of IXICO PLC?
Mr. Bram Goorden is the Chief Executive Officer of IXICO PLC, joining the firm since 2024.
What is the price performance of PHYOF stock?
The current price of PHYOF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for IXICO PLC?
IXICO PLC belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is IXICO PLC market cap?
IXICO PLC's current market cap is $0
Is IXICO PLC a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for IXICO PLC, including 4 strong buy, 4 buy, 1 hold, 0 sell, and 4 strong sell
